Literature DB >> 18816128

The first synthesis of a novel 5:7:5-fused diimidazodiazepine ring system and some of its chemical properties.

Raj Kumar1, Ravi K Ujjinamatada, Ramachandra S Hosmane.   

Abstract

The first synthesis of a novel 5:7:5-fused heterocyclic ring system, a diimidazodiazepine, is reported. The propensity of the ring system to undergo facile, acid-catalyzed nucleophilic addition reactions by neutral carbon and nitrogen nucleophiles has been explored. The ring system has potential future applications in mechanistic studies of formation and repair of DNA interstrand cross-links.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18816128      PMCID： PMC2652043          DOI： 10.1021/ol8020176

Source DB:  PubMed          Journal:  Org Lett        ISSN： 1523-7052            Impact factor:   6.005


  8 in total

Review 1.  Preparation of interstrand cross-linked DNA oligonucleotide duplexes.

Authors:  David M Noll; Anne M Noronha; Christopher J Wilds; Paul S Miller
Journal:  Front Biosci       Date:  2004-01-01

2.  Mispair-aligned N3T-alkyl-N3T interstrand cross-linked DNA: synthesis and characterization of duplexes with interstrand cross-links of variable lengths.

Authors:  Christopher J Wilds; Anne M Noronha; Sebastien Robidoux; Paul S Miller
Journal:  J Am Chem Soc       Date:  2004-08-04       Impact factor: 15.419

3.  Synthesis of a duplex oligonucleotide containing a nitrogen mustard interstrand DNA-DNA cross-link.

Authors:  J O Ojwang; D A Grueneberg; E L Loechler
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

Review 4.  Formation and repair of interstrand cross-links in DNA.

Authors:  David M Noll; Tracey McGregor Mason; Paul S Miller
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

Review 5.  Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance.

Authors:  P J McHugh; V J Spanswick; J A Hartley
Journal:  Lancet Oncol       Date:  2001-08       Impact factor: 41.316

6.  Structure of a DNA repair substrate containing an alkyl interstrand cross-link at 1.65 A resolution.

Authors:  Matthew C Swenson; Shanthi R Paranawithana; Paul S Miller; Clara L Kielkopf
Journal:  Biochemistry       Date:  2007-03-22       Impact factor: 3.162

7.  N(4)C-ethyl-N(4)C cross-linked DNA: synthesis and characterization of duplexes with interstrand cross-links of different orientations.

Authors:  Anne M Noronha; David M Noll; Christopher J Wilds; Paul S Miller
Journal:  Biochemistry       Date:  2002-01-22       Impact factor: 3.162

8.  Efficient synthesis of 4,4'-bi-1H-imidazol-2-ones from 5-amino-alpha-imino-1H-imidazole-4-acetonitriles and isocyanates.

Authors:  Alice M Dias; Isabel Cabral; M Fernanda Proença; Brian L Booth
Journal:  J Org Chem       Date:  2002-08-09       Impact factor: 4.354
  8 in total
  12 in total

1.  Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4',5'-f][1,3]diazepines.

Authors:  Atul Kondaskar; Shilpi Kondaskar; James C Fishbein; Brandon A Carter-Cooper; Rena G Lapidus; Mariola Sadowska; Martin J Edelman; Ramachandra S Hosmane
Journal:  Bioorg Med Chem       Date:  2012-12-11       Impact factor: 3.641

2.  Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System.

Authors:  Atul Kondaskar; Shilpi Kondaskar; Raj Kumar; James C Fishbein; Nidal Muvarak; Rena G Lapidus; Mariola Sadowska; Martin J Edelman; Guus M Bol; Farhad Vesuna; Venu Raman; Ramachandra S Hosmane
Journal:  ACS Med Chem Lett       Date:  2010-12-31       Impact factor: 4.345

3.  In vitro anti-cancer activity of doxorubicin against human RNA helicase, DDX3.

Authors:  Mahendran Botlagunta; Bhulakshmi Kollapalli; Lavanya Kakarla; Siva Priya Gajarla; Sai Pujitha Gade; Chandra Lekha Dadi; Akhila Penumadu; Shaik Javeed
Journal:  Bioinformation       Date:  2016-10-18

4.  RK-33 Is a Broad-Spectrum Antiviral Agent That Targets DEAD-Box RNA Helicase DDX3X.

Authors:  Sundy N Y Yang; Sarah C Atkinson; Michelle D Audsley; Steven M Heaton; David A Jans; Natalie A Borg
Journal:  Cells       Date:  2020-01-09       Impact factor: 6.600

5.  PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3.

Authors:  Guus Martinus Bol; Raheela Khan; Marise Rosa Heerma van Voss; Saritha Tantravedi; Dorian Korz; Yoshinori Kato; Venu Raman
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-02       Impact factor: 3.333

6.  Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanism via epidermal growth factor receptor (EGFR) inhibition.

Authors:  Sourav Kalra; Gaurav Joshi; Manvendra Kumar; Sahil Arora; Harsimrat Kaur; Sandeep Singh; Anjana Munshi; Raj Kumar
Journal:  RSC Med Chem       Date:  2020-07-08

7.  Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer.

Authors:  Guus M Bol; Venu Raman; Petra van der Groep; Jeroen F Vermeulen; Arvind H Patel; Elsken van der Wall; Paul J van Diest
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

8.  Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.

Authors:  Sabindra K Samal; Samapika Routray; Ganesh Kumar Veeramachaneni; Rupesh Dash; Mahendran Botlagunta
Journal:  Sci Rep       Date:  2015-04-28       Impact factor: 4.379

9.  NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.

Authors:  Min Xie; Farhad Vesuna; Mahendran Botlagunta; Guus Martinus Bol; Ashley Irving; Yehudit Bergman; Ramachandra S Hosmane; Yoshinori Kato; Paul T Winnard; Venu Raman
Journal:  Oncotarget       Date:  2015-10-06

Review 10.  DDX3, a potential target for cancer treatment.

Authors:  Guus Martinus Bol; Min Xie; Venu Raman
Journal:  Mol Cancer       Date:  2015-11-05       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.